These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

617 related items for PubMed ID: 18554462

  • 1. [Clinical importance of minimal residual disease testing in the therapy of childhood B-cell acute lymphoblastic leukemia].
    Ye QD, Gu LJ, Tang JY, Xue HL, Chen J, Pan C, Chen J, Dong L, Zhou M, Jiang LM.
    Zhongguo Dang Dai Er Ke Za Zhi; 2008 Jun; 10(3):333-6. PubMed ID: 18554462
    [Abstract] [Full Text] [Related]

  • 2. [Prognostic factors for childhood acute non-mature B-lymphoblastic leukemia].
    Jiang H, Gu LJ, Xue HL, Tang JY, Chen J, Pan C, Chen J, Xu C, Dong L, Zhou M.
    Zhongguo Dang Dai Er Ke Za Zhi; 2008 Jun; 10(3):290-4. PubMed ID: 18554450
    [Abstract] [Full Text] [Related]

  • 3. Prognostic role of minimal residual disease in mature B-cell acute lymphoblastic leukemia of childhood.
    Mussolin L, Pillon M, Conter V, Piglione M, Lo Nigro L, Pierani P, Micalizzi C, Buffardi S, Basso G, Zanesco L, Rosolen A.
    J Clin Oncol; 2007 Nov 20; 25(33):5254-61. PubMed ID: 18024872
    [Abstract] [Full Text] [Related]

  • 4. [Prognostic value of minimal residual disease in childhood B-cell acute lymphoblastic leukemia].
    Tie LJ, Gu LJ, Chen J, Jiang LM, Dong L, Pan C, Ye H, Song DL, Xue HL, Tang JY, Wang YP, Chen J.
    Zhonghua Xue Ye Xue Za Zhi; 2006 Feb 20; 27(2):120-3. PubMed ID: 16732969
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [Minimal residual disease analysis in acute lymphoblastic leukemia of childhood within the framework of COALL Study: results of an induction therapy without asparaginase].
    zur Stadt U, Harms DO, Schlüter S, Jorch N, Spaar HJ, Nürnberger W, Völpel S, Gutjahr P, Schrappe M, Janka G, Kabisch H.
    Klin Padiatr; 2000 Feb 20; 212(4):169-73. PubMed ID: 10994545
    [Abstract] [Full Text] [Related]

  • 7. Prognostic value of early treatment response in children with acute lymphoblastic leukemia: a single institution experience in Shanghai, China.
    Tie LJ, Gu LJ, Song DL, Jiang LM, Xue HL, Tang JY, Dong L, Pan C, Chen J, Ye H, Chen J.
    Zhongguo Dang Dai Er Ke Za Zhi; 2009 Jan 20; 11(1):5-9. PubMed ID: 19149913
    [Abstract] [Full Text] [Related]

  • 8. [Evaluation on protocol SCMS-ALL-2005 for childhood B lineage acute lymphoblastic leukemia].
    Tang JY, Xue HL, Chen J, Pan C, Li BS, Gu LJ, Dong L, Hu WT, Shen SH, Zhou M, Ye QD, Jiang H, Luo CY.
    Zhonghua Yi Xue Za Zhi; 2012 Feb 28; 92(8):546-50. PubMed ID: 22490159
    [Abstract] [Full Text] [Related]

  • 9. Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials.
    Attarbaschi A, Mann G, Panzer-Grümayer R, Röttgers S, Steiner M, König M, Csinady E, Dworzak MN, Seidel M, Janousek D, Möricke A, Reichelt C, Harbott J, Schrappe M, Gadner H, Haas OA.
    J Clin Oncol; 2008 Jun 20; 26(18):3046-50. PubMed ID: 18565891
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Slower molecular response to treatment predicts poor outcome in patients with TEL/AML1 positive acute lymphoblastic leukemia: prospective real-time quantitative reverse transcriptase-polymerase chain reaction study.
    Madzo J, Zuna J, Muzíková K, Kalinová M, Krejcí O, Hrusák O, Otová B, Starý J, Trka J.
    Cancer; 2003 Jan 01; 97(1):105-13. PubMed ID: 12491511
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Therapeutic effectiveness of the ALL-XH-99 protocol for childhood acute lymphoblastic leukemia.
    Wang YR, Jin RM, Xu JW, Xiao Y, Zhou DF, Zhang ZQ.
    Zhongguo Dang Dai Er Ke Za Zhi; 2008 Feb 01; 10(1):1-4. PubMed ID: 18289459
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow.
    Basso G, Veltroni M, Valsecchi MG, Dworzak MN, Ratei R, Silvestri D, Benetello A, Buldini B, Maglia O, Masera G, Conter V, Arico M, Biondi A, Gaipa G.
    J Clin Oncol; 2009 Nov 01; 27(31):5168-74. PubMed ID: 19805690
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Detectable minimal residual disease before allogeneic hematopoietic stem cell transplantation predicts extremely poor prognosis in children with acute lymphoblastic leukemia.
    Sramkova L, Muzikova K, Fronkova E, Krejci O, Sedlacek P, Formankova R, Mejstrikova E, Stary J, Trka J.
    Pediatr Blood Cancer; 2007 Jan 01; 48(1):93-100. PubMed ID: 16521130
    [Abstract] [Full Text] [Related]

  • 20. Status of minimal residual disease after induction predicts outcome in both standard and high-risk Ph-negative adult acute lymphoblastic leukaemia. The Polish Adult Leukemia Group ALL 4-2002 MRD Study.
    Holowiecki J, Krawczyk-Kulis M, Giebel S, Jagoda K, Stella-Holowiecka B, Piatkowska-Jakubas B, Paluszewska M, Seferynska I, Lewandowski K, Kielbinski M, Czyz A, Balana-Nowak A, Król M, Skotnicki AB, Jedrzejczak WW, Warzocha K, Lange A, Hellmann A.
    Br J Haematol; 2008 Jun 01; 142(2):227-37. PubMed ID: 18492099
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.